Sign inJoin waitlistJoin the waitlist

David Russler-Germain

Instructor · Washington University/B-JH/SLCH Consortium

Credentials: · · · · ·

History

Washington University/B-JH/SLCH Consortium
Present
Washington University/B-JH/SLCH Consortium
Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2020–2023
Internal Medicine
Barnes-Jewish Hospital
2017–2020
Washington University School of Medicine
2013–2017
Stanford University, Stanford, CA
2009–2013

Research

The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers
Cancer Cell · 2014 · First of 11 authors · 384 citations
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
Proceedings of the National Academy of Sciences of the United States of America · 2009 · 183 citations
CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression
Cell · 2017 · 174 citations

Todd Fehniger
19 papers
Nancy Bartlett
10 papers
AZ
Alice Zhou
8 papers · 2 as a resident
Amanda Cashen
8 papers
BK
Brad Kahl
8 papers
CC
Celia Cubitt
8 papers
Miriam Jacobs
7 papers
Kilannin Krysiak
4 papers
Neha Mehta-Shah
4 papers
TL
Timothy Ley
4 papers
AG
Aaron Goodman
3 papers
Ajay Major
3 papers · 1 as a fellow

Clinical trials

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
Principal investigator · Active not recruiting · Phase 1
Washington University School of Medicine
2023–2029
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Principal investigator · Active not recruiting · Phase 2
Washington University School of Medicine
2022–2029
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Site PI · Recruiting
Tempus AI
2026–2035
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Site PI · Recruiting · Phase 2
University of Washington
2025–2033